Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2009

Highlights from the Q2 2009 review of medical device and in vitro diagnostics/research dealmaking: Financings by medical device companies jumped an impressive 62% over Q1 to $847 million--primarily from private VC rounds that contributed over 90% of the total deal volume with 52 early- and late-stage transactions--indicating a possible rebound in fundraising. Medical device M&As, on the other hand, proved to be a disappointment with only ten deals raising $794 million, most of which was Covidien's $470 million cash purchase of Vnus Medical. Although there were no big mergers, some device firms instead turned to the strategic alliance as a way to gain inexpensive products and technologies. On the in vitro diagnostics/research side, financing activity captured over three times the previous quarter's dollars through 12 deals totaling $302 million, however, almost 80% of that amount was from Beckman Coulter's $239 million FOPO. VC rounds only averaged $6 million apiece, with early- and late-stage rounds together bringing in $43 million. M&A in this industry segment was almost non-existent with only two transactions adding up to $358 million, a mere third of Q1 M&A deal volume.

In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking—for the second quarter of 2009. Our data come from Elsevier's Strategic Transactions.

Amanda Micklus and Maureen Riordan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By 

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy